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Latent and active levels of cerebral matrix metalloproteinase 9 (MMP-9) are elevated in 
neurological diseases and brain injuries, contributing to neurological damage and poor clinical 
outcomes. This study aimed developing peptide-based nanoparticles with ability to cross the 
blood-brain-barrier (BBB) and inhibit MMP-9. 
Three amphiphilic peptides were synthesised containing brain-targeting ligands (HAIYPRH or 
CKAPETALC) conjugated with MMP-9 inhibiting peptide (CTTHWGFTLC) linked by 
glycine (spacer) at the N-terminus, and the peptide sequences were conjugated at the N-
terminus to cholesterol. 19F-NMR assay was developed to measure MMP-9 inhibition. Cell 
toxicity was evaluated by the LDH assay, and dialysis studies were conducted with/without 
fetal bovine serum. An in vitro model was employed to evaluate the ability of nanoparticles 
crossing the BBB.  
The amphiphilic peptide (Cholesterol-GGGCTTHWGFTLCHAIYPRH) formed nanoparticles 
(average size of 202.8 nm) with ability to cross the BBB model. MMP-9 inhibiting 
nanoparticles were non-toxic to cells, and reduced MMP-9 activity from kobs of 4.5×10
-6s-1 to 
complete inhibition. Dialysis studies showed that nanoparticles did not disassemble by extreme 
dilution (40 folds), but gradually hydrolysed by serum enzymes.  
In conclusion, the MMP-9 inhibiting nanoparticles reduced the activity of MMP-9, with 
acceptable serum stability, minimal cell toxicity and ability to cross the in vitro BBB model.  
Keywords: MMP-9 inhibitor, nanoparticles, brain drug delivery, blood-brain-barrier  
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1. Introduction  
The matrix metalloproteinases (MMPs) belonging to the metzincin family.1 In humans, 23 
different MMPs have been discovered2 and are divided into soluble-type MMPs and membrane 
bound MMPs.3 MMPs are sub-grouped into collagenases, gelatinases, stromelysins and 
matrilysins.4 Collectively MMPs metabolize extracellular matrix. 1,3,5 
Matrix metalloproteinase 9 (MMP-9) or gelatinase B is a member of large MMPs family. 
MMP-9 not only metabolize the denatured collagen6 but also breakdown various collagens, 
activate and modify cytokine and chemokines.7 MMP-9 is expressed in the CNS as well as the 
peripheral nervous systems. MMP-9 expression is elevated in neurological diseases such as 
traumatic brain injury,8 and multiple sclerosis (MS);9 and its high levels are believed to be 
associated with poor outcomes.8 Kumari et al 2011 showed that the proteolytic activity of 
MMP-9 was significantly increased in the ipsilateral hemispheres of db/db mice compared to 
db/+ mice and this increased the chance of infarction in db/db mice.10 MMP-9 expression 
correlated with stroke severity and poor outcome, and clinical trials were recommended testing 
agents antagonizing MMP-9 effects.11 
Various efforts have been made to develop inhibitors for MMP-9 partially or completely. 
For example, Nyormoi et al. 2003 have reported an inhibtor of MMP-9 (compound 5a), that 
has antineoplastic activity. Furthermore, They reported that compound 5a did not act directly 
on mitochondia but it exhibits antineoplastic activity by ligand-receptor interaction and caspase 
8 activation.12 As another example, racemic ND-336, a selective MMP-9 inhibitor has 
demonstrated higher healing ability compared to becaplermin as MMP-9 promotes the 
damaging effects in diabetic foot ulcers.13 Several MMP-9 inhibitors have been reported such 
as GS-5745,14  and AQU-118, 15 but there is still need to identify an inhibitor with opimum 
activity and less  toxicity. To achieve this target, MMP-9-siRNA was conjugated to quantum 
dots with a size of 15 nm. The aim was to downregulate MMP-9 expression in brain 
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microvascular endothelial cells.16 To use a magnetic platform to guide nanoparticles (NPs) to 
the brain, tissue inhibitor of matrix metalloproteinases 1 (TIMP-1), an endogenous inhibitor of 
matrix metalloproteinases, was surface adsorbed on magnetic NPs (size of 10 nm). In the 
presence of static magnet, the NPs crossed human in vitro blood-brain-barrier (BBB) model.17 
In another study, TIMP-1 loaded poly(lactic-co-glycolic acid) (PLGA) NPs were 
developed to enhance delivery of TIMP-1 to the brain. The NPs coated with polysorbate 80 
(PS80) and penetrated the BBB following intravenous injections into mice.18 On the other hand 
in another work, PLGA NPs (260 nm) were coated with PS80, which contained β-carotene (to 
reduce oxidative stress in organs). After intravenous administration, the majority of these NPs 
were observed to accumulate in the lungs rather than the brains of rats (2000 nmol/g in lungs 
compared to 0.2 nmol/g in the brain).19 This study shows that NPs should be decorated with 
brain targeting ligands for the treatment of brain diseases.20 Furthermore, Chen et al found that 
associated adeno virus (AAV) presenting an epitope of WPFYGTP showed 35 times greater 
efficiency in targeting the brain than the liver. Interestingly, AAVs with epitopes for brain 
microvessels of wild-type mice were not effective for mucopolysaccharidosis type VII mouse 
brain.20 Therefore, brain targeting ligands may be suitable for certain diseases, but not for 
others. Hence, the brain targeting ligand should be chosen in relation to the brain disease. 
Although the above approaches are effective methods to inhibit MMP-9 in brain diseases, there 
is a need for nanoparticles that can be administered intravenously with specifically targeting 
the brain to inhibit MMP-9 for a few hours, but that are degraded by the brain/systemically. 
This is because, human studies indicated that the useful therapeutic window for MMP-9 
inhibition is up to 72 h postinjury in traumatic brain injury.21 It is believed that MMPs such as 
MMP-9 cause detrimental effects during early ischemic phase, but they are beneficial for 
reestablishment of cerebral blood flow and angiogenesis.22-25   
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Minocycline with MMP-9 inhibiting property26 has been used in clinical trials with success 
for the treatment of stroke.27 However, as high doses are required (10 mg/kg), and the toxicity 
of the drug has been fatal for some patients.27 Another recent clinical trial showed the benefits 
of using minocycline (200 mg/day) for 6 months in patients to prevent the risk of conversion 
from clinically isolated demyelinating syndrome to multiple sclerosis.28 However, the drug side 
effects (rash, dizziness, and dental discoloration) were frequent in the patients treated with 
minocycline, and in cases resulted withdrawal from the trial.28 These further indicate the 
necessity of using brain-targeted delivery systems such as nanoparticles or nanocarriers to 
minimise drug side effects. Administration of selective MMP-9 inhibitor (SB 3CT) improved 
long-term neuro-behavioural in a mouse model of traumatic brain injury following 
intraperitoneal administration.29 SB 3CT and its metabolite -OH SB 3CT were rapidly 
adsorbed and distributed to the brain,29 however, SB 3CT exhibits poor water solubility, which 
might have prevented its use in clinical trials since its discovery in 2000.30 Therefore, clearly 
there is a need for brain targeting MMP-9 inhibitor with minimal side effects, low cost and 
scalability. 
The present study was inspired by the work of Koivunen, E. et al 1999, who found that the 
synthetic peptide CTTHWGFTLC (cyclic disulfide-bonded) is a potent inhibitor of MMP-9,31 
although other MMP-9 inhibiting peptides have been reported.32-34 Furthermore, 
CTTHWGFTLC is a water-soluble peptide31, and it is relatively a short peptide, which would 
be an advantage in a large-scale production. This study aimed to synthesis amphiphilic peptides 
that self-assemble to form NPs incorporating the MMP-9 inhibiting peptide with the ability to 
cross the BBB for the treatment of neurodegenerative diseases and brain injuries. This work 
developed NPs containing a brain targeting peptide sequence (HAIYPRH) [HAI peptide], but 
not for a specific brain disease (Figure 1). In vitro experiments were conducted to evaluate the 
efficacy of the NPs in inhibiting MMP-9 enzyme and cytotoxicity of these NPs. In this work 
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we employed the hCMEC/D3 cell line to develop static in vitro BBB model.35,36 Amphiphilic 
peptides have been developed previously to target the brain, 37,38 but not for the treatment of 
brain diseases such as stroke or MS. This study was a proof-of-concept that brain targeting NPs 
containing MMP-9 inhibiting peptide are able to reduce MMP-9 activity and cross the BBB. 
 
2. Materials and Methods 
2.1 Materials 
All L-Fmoc amino acids, Oxyma and ProTide® resin were from CEM (Buckingham, UK). 
N,N′-Diisopropylcarbodiimide (DIC), piperidine, cholesteryl chloroformate (CHF), 
trifluoroacetic acid (TFA), triisopropylsilane (TIPS), acetonitrile, formic acid and N,N-
diisopropylethylamine (DIPEA), trizma base (Tris), sodium chloride, Brij35, N-(3-
Aminopropyl) methacrylamide hydrochloride (APMA) and cellulose dialysis tubing with 
molecular weight cut-off 10000 were from Sigma-Aldrich (Dorset, UK). Fmoc-L-4-
fluorophenylalanine was from Fluorochem® (Hadfield, UK). Dimethylformamide (DMF), 1-
(2-Pyridylazo)-2-naphthol (PAN) and diethyl ether were from Acros Organics® 
(Loughborough, UK). MMP-9 recombinant human protein, His Tag (10327H08H5), Pierce 
LDH cytotoxicity assay kit and calcium chloride dihydrate (CaCl2) were from ThermoFisher 
Scientific® (Paisley, UK). hCMEC/D3 cell line and EndoGRO-MV kit media supplemented 
with (EndoGRO-LS supplement, rh EGF, L-Glutamine, Hydrocortisone hemisuccinate, 
heparin sulfate, ascorbic acid and fetal bovine serum) were purchased from Merck Millipore ( 
Massachusetts, USA). Passage number used was from 1-11 with Lot number of 3130216. 
Carbon coated Cu grids were from Agar Scientific Ltd (Stansted, UK). FITC-dextran with a 
molecular weight of 70 kDa was purchased from Sigma-Aldrich (Dorset, UK). Polyethylene 




2.2.1. Solid‐Phase Peptide Synthesis (SPPS) 
Peptides were synthesised using a CEM Liberty Blue® automated microwave-assisted 
peptide synthesiser.39 Briefly, 147 mg of Rink Amide ProTide resin (loading capacity 0.61 
mmol/g) was transferred into a reaction vessel and was swollen in DMF. Typical Fmoc-
deprotection required 20% piperidine in DMF for 90 seconds at 90oC. 1 M DIC and Oxyma 
solutions were used as activator and coupling reagents, respectively. 0.2 M solutions of amino 
acids in DMF were used for synthesis. Amino acids were single coupled at 90oC, except 
cysteine (Cys) coupled at 50oC and arginine (Arg) double coupled at 75oC. 
2.2.2. Liquid Chromatography-Mass Spectrometry (LC/MS) Analysis 
The validity of the synthesis was confirmed by high performance liquid chromatography 
(HPLC) and liquid chromatography and mass spectroscopy (LC/MS), as reported previously.39 
When the synthesis of peptides was accomplished, peptides were dispersed in 1 mL of MeOH 
and 0.1 mL of water respectively and sonicated for 15 minutes until fully dispersed prior to 
characterisation by liquid chromatography-mass spectrometry (Waters 2695 Separation 
Module linked with Quattro Premier Micromass). Samples were prepared in a mixture of water, 
acetonitrile and formic acid (80%: 20%: 0.1%) and separated (20 µL injection) on a XBridge® 
Peptide BEH C18 column (130 Ă, 5 µm and 4.6 mm x 150 mm) using a gradient elution of two 
mobile phases (A - water: formic acid 99.9%: 0.1%, B - methanol: formic acid; 99.9%: 0.1%). 
LC/MS (ESI in positive/negative switching mode, mass range 0-2000 Da) was used confirm 
the required m/z of the peptides present as well as other molecules/ impurities present. The 
tandem mass spectrum was used against the database to search for the required m/z. Analysis 
was performed using MassLynx mass spectroscopy software (Waters).  
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2.2.3.  High Performance Liquid Chromatography (HPLC)  
Synthesised peptides were characterised using analytical HPLC as reported previously.39 
Agilent 1200 Series was employed for HPLC analysis. A small amount of the sample was 
dissolved in 1 mL of MeOH and 0.5 mL of deionized water. The injection volume was 20 µL 
and the UV detection was 224-280 nm. Phenomenex C18 analytical HPLC column (3.6 µm 
particle size, 4.6 × 150 mm column) with a binary eluent system comprising MeOH / H2O (18 
min gradient: 5-95% with 0.1% formic acid) as mobile phase. Operating pressures were in the 
range of 2000-3000 PSI. 
2.2.4. Conjugation of CHF to Peptides  
Once the peptide sequence was synthesised and chemical structure was analysed, 
conjugation of CHF was commenced to produce amphiphilic peptides, as reported 
previously.37 Briefly, ProTide resin-bound peptide (1 eq. based on loading capacity 0.61 
mmol/g) was added to a solution containing CHF (2 eq.) and DIPEA (4 eq.) in DMF (4 mL) at 
40oC.37 The Kaiser test was performed to assess the completeness of conjugation and the 
process was repeated until complete coupling. The amphiphilic peptide was cleaved from the 
resin by reacting with 5 mL of cleavage cocktail [comprising TFA, TIPS and water (9:0.5:0.5 
v/v)] with regular shaking at room temperature for 4 h. The solution was then filtered into ice 
cold diethyl ether followed by centrifugation. Precipitated amphiphilic peptide was repeatedly 
resuspended in diethyl ether with subsequent centrifugation for three times. Diethyl ether was 
evaporated by leaving it overnight in the fridge. Amphiphilic Peptides were dispersed in water, 
flash frozen and freeze dried to obtain the conjugated peptide as powder. No further steps were 
taken to cyclise the cysteine amino acids in the peptides or purify the conjugated peptides. 
Excess TFA was removed by lyophilisation after cleavage/precipitation of the conjugated 
peptide. Therefore, the conjugated peptide was a TFA salt. 
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2.2.5. MMP-9 Enzyme Activation 
The enzyme activation was achieved by following manufacturer’s protocol. A TCNB 
buffer [Tris (50mM), CaCl2 (10mM), NaCl (150 mM) and Brij 35 (0.05%)] was prepared using 
Trizma base (Tris) at a concentration of 200 mM, calcium chloride dihydrate (CaCl2) at a 
concentration of 40 mM, sodium chloride (NaCl) at a concentration of 600 mM, Brij35 at a 
concentration of 0.2%. Each of these components was dissolved in 10 mL of sterile water 
separately, then 1 mL from each solution was transferred into another container and the desired 
concentration was achieved. To the 5 μg MMP-9 (ThermoFisher, REF – 10327-H08H-5, LOT 
–LCL09AU0402) 900 μL of the TCNB buffer was added in 100 μL increments to dissolve the 
sample. Then, 100 μL of APMA was added to give a concentration of 1 mM. The final solution 
of MMP-9 was obtained with the concentration of 64.4 nM. This solution was incubated for 24 
h at 37C. Following this, 3 mL of TCNB buffer was added to make a 16 nM solution of MMP-
9. One mL of this solutions was further diluted to 8 mL in TCNB buffer to give a 2 nM solution 
for use in NMR studies.  
2.2.6. Dynamic Light Scattering (DLS) analysis and Zeta Potential Measurement 
Particle size was measured by using Malvern Zetasizer Nano ZS® (Malvern, Worcestershire, 
UK), containing a He-Ne laser source (λ= 632.8 nm, 22 mW output power). Cuvettes used 
were DTS0012. The refractive index of 1.3 and viscosity of 0.9 cP were used for water. Three 
readings were performed on the amphiphilic peptide samples dispersed in water. The same 
instrument was used to measure the zeta potential. All measurements were carried out in 
triplicates, means and standard deviations (SD) were also calculated. 
2.2.7. Transmission Electron Microscopy (TEM) 
Peptide nanocarriers were visualised and characterized morphologically by FEI Morgagni 
transmission electron microscope. Carbon filmed copper grids were used. 2.5 mg/mL peptide 
solution was prepared in distilled water. A small droplet of the peptide solution was placed on 
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the grid and left to dry. Samples were analysed in the TEM after drying. No staining (negative 
of positive) was used. 
2.2.8. Preparing Nanoparticle Dispersions 
Sterile deionised water was used to prepare nanoparticle dispersions. The procedure was 
carried-out in a disinfected laminar flow cabinet to prepare 2.5 mg/mL suspension of the 
amphiphilic peptide. Bath sonication of the suspension was then carried out for 1 h and 45 min 
to disperse the amphiphilic peptide particles and form the nanoparticle colloidal dispersions 
VWR Ultrasonic Cleaner USC 300 TH 2.8 L 45 kHz (VWR International) with 160 W 
(effective 80 W) ultrasonic power.  
2.2.9. Dialysis  
Approximately 15 cm of dialysis tubing was soaked in a beaker of water for 5 min. In a 
separate beaker, 40 mL of distilled particle free water was added with a magnetic stirrer bar. 
Once the tubing was flexible, one end was tied, 1 ml of the amphiphilic peptide nanocarrier 
suspension was placed inside it and the other end was tied to seal. This was then placed into 
the 40 mL of water (40-folds dilution) containing the magnetic bar; secured using an elastic 
band and then the beaker was placed on a stirring plate. The parameters on the fluorescence 
spectrophotometer were set with excitation at 270 nm, emission starting at 300 nm and stopping 
at 400 nm with the slit width set at 20 nm. The background fluorescence was measured using 
just water in a four clear side quartz cuvette using the fluorescence spectrophotometer 
(VARIAN CARY Eclipse, UK). The intensity of fluorescence of the surrounding water was 
then tested at time 0, 1, 2, 3, 4, 5, 6 and 24 h. At each sampling time point, 3 mL (1x 3 mL) 
from outside of the dialysis bag was placed in the 4-clear side cuvette and analysed using the 
fluorescence spectrophotometry and the intensity was measured to determine the release of the 
amphiphilic peptide through the dialysis membrane. Each sample was returned to the beaker 
after each test to keep the volume at 40 mL. 
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The same dialysis procedure was then carried out with the NPs dispersed in fetal bovine 
serum (FBS) with distilled water on the outside of the bag. All release studies replicated three 
times. 
2.2.10. Enzyme Inhibition Study and Enzyme Kinetic Evaluations 
Enzymatic studies (inhibitory effects of NPs) were conducted by using the Bruker® 
Ascend™ 600 MHz NMR spectrometer. One-dimensional (1D) fluorine-19 (19F; 564.7 MHz) 
NMR experiments were performed with proton decoupling at room temperature (298 K). An 
in-house developed highly sensitive MMP-9 peptide (TY-26, results due to be published 
separately) with 4-fluorophenylalanine was used to analyse the inhibitory effects of NPs. A 
sample (350 µL) of MMP-9 sensitive peptide (5 mg/mL) was added to NMR tube along with 
400 μL of the activated MMP-9. This was the control sample. The same solution and 350 µL 
of MMP-9 inhibiting nanocarrier aqueous dispersion was added to the second NMR tube as the 
test sample. Peptide products and metabolites containing 4-fluorophenylalanine were observed 
as singlets with different characteristic chemical shifts. Chemical shift values were calibrated 
to TFA (-76.55 ppm) as the internal standard. Data obtained was viewed and analysed by using 
TopSpin® and Dynamics centre 2.4.5 (Bruker®) was used for processing and calculating 
enzyme kinetics. Further control tests were conducted by evaluating MMP-9 sensitive peptide 
in the TCNB buffer and degradation of an MMP-9 non-responsive peptide (TY-27: GGYGQ-
GYW19FG) in the presence of MMP-9. 
2.2.11. Assessment of Cell Death Induction  
The lactate dehydrogenase (LDH) assay was used to assess the potential toxicity of the 
MMP-9 inhibitory NPs. HeLa cells were grown in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% FBS and 2 mM L-glutamine. They were then washed with 
phosphate-buffered saline, trypsinised, re-suspended in the growth medium, counted and 
seeded into an opaque, micro-clear, flat bottom 96 well tissue culture plate at a density of 7.5 
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x 104 cells/mL (7500cells/ well at 100 µL/well). A blank control well with no cells (complete 
medium only) was included. The experimental design included triplicate wells to be later used 
for LDH assay controls. The 96 well plate was then incubated overnight at 37C with a 5% 
CO2 supply. Then the nanocarriers were added to the culture wells in triplicate. Sterile water 
was added to the negative control wells. The treated 96 well plate was then incubated for 24 h 
at 37C and 5% CO2, at the end of which, the LDH assay was carried out according to the 
manufacturer’s protocol (ThermoFisher, Pierce LH Cytotoxicity Assay Kit, Cat. No. 88953). 
Included in the design were a spontaneous LDH activity control (10 µL of sterile water, to 
capture minimum LDH release, i.e., completely healthy cells representing 0% LDH release) 
and a maximum LDH activity control (10 µL of 10x lysis buffer, expected to fully lyse the 
cells, indicative of 100% LDH release). The 96 well plate was then incubated for a further 45 
min at 37C with a 5% CO2 supply. Following this incubation, 50 μL of medium from each 
test or control well was transferred into a new 96 well flat-bottom plate. Then 50 μL of reaction 
mixture was added to each of these wells and the plate was tapped gently. This plate was then 
incubated at room temperature for 30 minutes whilst covered in foil to protect it from light, 
after which, 50 μL of stop solution (strong acid) was added to each of the wells and was mixed 
by gentle tapping. Any bubbles made were removed with a syringe needle. Then with the 
Clariostar plate reader (BMG Labtech), the value for the blank well (non-cell-containing) was 
subtracted from the negative control value and each treatment value. The resultant value at 680 
nm was then subtracted from the corresponding resultant value at 480 nm. These final values 
were then analysed by expressing the value for the negative control or for each treatment as a 
percentage of the maximum LDH release value. Three cell passages were studied. 
2.2.12. Blood Brain Barrier In Vitro Model Preparation and Transmigration Assay 
The BBB in vitro model was constructed using protocol supplied by Merck Millipore. 
Permeability across the BBB was conducted by using an in vitro BBB model utilising 
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immortalized human brain endothelial cell line hCMEC/D3. Briefly, 90000 cells were seeded 
in 24 well TC-inserts and 500 µL of EndoGRO culture media with supplements (including 
serum and VEGF) was added; and 1.6 mL of the same medium was added in the well containing 
the insert. The plate was placed in the incubator at 37oC with 5% CO2. After 24 h, 
transepithelial/endothelial electrical resistance (TEER) was measured by using EVOM2 (world 
precision instruments, USA). Prior to the permeability experiment, sensitivity of the BBB 
monolayer was tested by using histamine and cimetidine. Briefly, media were replaced and 
histamine was added in to inserts at a final concentration of 50 µM. The plate was incubated 
for 30 min at 37oC. TEER values were measured at 36 h. Cells were washed with sterile PBS 
buffer and fresh media were added. Cimetidine was added into inserts at a final concertation of 
50 µM. The plate was incubated for 1 h and TEER values were measured. Culture media were 
replaced with fresh media and incubated for 12 h. TEER values were measured again after 48 
h. Furthermore, TEER values were determined after transmigration tests. All measurements 
were carried out in triplicates, means and standard deviations (SD) were also calculated. 
For transmigration studies, hCMEC/D3 cells were seeded at 90000 cells/insert for 48 h and 
TEER values were measured to ensure formation of the biological barrier. The media were 
replaced with fresh media and NPs were added to the apical side to achieve final concentration 
of 0.4 mg/mL. Concentration of NPs transmigrated the BBB monolayer was assessed by 
measuring the fluorescence in basolateral compartment at λexc 270 nm and λems 341 nm by using 
SpectraMax i3x Multi-Mode Detection plate reader (Molecular Devices, USA).  
The transmigration of NPs across the BBB was calculated from Equation 1: 
% 𝑜𝑓 𝑁𝑃𝑠 𝑖𝑛 𝐵𝑎𝑠𝑎𝑙 𝐶ℎ𝑎𝑚𝑒𝑟 =
𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑜𝑓 𝑁𝑃 𝑎𝑡 𝑡𝑖𝑚𝑒 𝑡 𝑖𝑛 𝑏𝑎𝑠𝑎𝑙 𝑐ℎ𝑎𝑚𝑏𝑒𝑟
𝐹𝑙𝑢𝑟𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑜𝑓 𝑇𝑜𝑡𝑎𝑙 𝑁𝑃 𝑖𝑛 𝑏𝑎𝑠𝑎𝑙 𝑐ℎ𝑎𝑚𝑏𝑒𝑟
× 100 
 Equation 1 
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Where “Fluorescence of Test NP at time t in basal chamber” indicates the fluorescence of 
NPs in the basolateral compartment at a certain time t; and “Fluorescence of Total NP” denotes 
the fluorescence of NPs when all NP sample was added into the basolateral compartment. 
Apparent permeability (Papp) was calculated as reported previously.40  
After final fluorescence measurements of NPs at time 24 h in the basolateral compartment, 
TEER values were measured again and media replaced with pre-heated fresh media. 10µL of 
FITC-Dextran solution (1mg/mL) was added to the apical side and florescence (λexc 485 nm, 
λems 520 nm) was measured in the basolateral compartment. The experiments were replicated 
in three separate runs. 
2.2.13. Statistical Analysis  
GraphPad Prism Software 8.0.1 for Windows (GraphPad Software, Inc., La Jolla, CA, 
USA) was used to conduct one-way analysis of variance (ANOVA) followed by Tukey’s post-
hoc test for multiple comparisons in order to identify any statistically-significant differences 
between the means of treatment groups. For statistical comparisons, P<0.05 was considered a 
statistically significant difference. 
3. Results 
3.1. Characterisation of Chemical Structure, Size Distribution, and Morphology of 
Nanoparticles  
Three types of amphiphilic peptides were examined (Table 1). In these compounds two 
types of brain targeting ligands were examined: MiniAp-3 (CKAPETALC),41 and HAI peptide 
(HAIYPRH).42 In addition, at the N terminus of the MMP-9 inhibitor peptide three glycine 
residues were incorporated as a spacer between the MMP-9 inhibitor peptide and cholesterol. 
The HPLC data (supplementary information S1 and S2) suggested the formation of disulphide 
bridges between cysteine amino acids in Peptide 1 and also Peptide 2 (peaks at retention time 
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of 13.7 and 14.0 min in Figure S1 and peaks at 15.9 and 16.4 min in Figure S2). For Peptide 3 
the peak at 17.5 min (Supp. Figure S3) would suggest the formation disulphide bridges between 
the cysteine amino acids in the peptide. These observations suggest in situ cyclisation of 
peptides (but not complete) upon cleavage of peptides from the resin, despite no intentional 
steps being taken to cyclise the peptides. LC/MS data confirmed successful synthesis of Peptide 
3 (Figure S4). Among these peptides, only peptide 3 with the sequence 
GGGCTTHWGFTLCHAIYPRH was successfully conjugated with cholesterol. The other two 
peptides did not show the conjugation with CHF by performing the Kaiser test. Therefore, the 
following results are presented for Peptide 3. LC/MS data and UV chromatogram indicated the 
conjugation of CHF to the peptide sequence (Supp. Figure S5 and S6). The calculated mass for 
conjugated Peptide 3 was 2626.13 Da; and m/z at 1314.5 was indicative of the doubly charged 
conjugated Peptide 3 with m/z at 876.9 indicating triply charged peptide and m/z at 738.5 
showing fragmentation of Peptide 3 from CHF. The MMP-9-inhibitor NPs had average size of 
202.8 ± 105.6 nm, with polydispersity index (PdI) of 0.2 (Figure 2), and zeta potential of +26.7 
mV. TEM images revealed irregular shape for MMP-9 inhibitor NPs (Figure 3). As this was a 
preliminary study and our expectation was that only conjugated peptides would form 
nanoparticles, then, we did not purify the conjugated peptide. 
3.2.MMP-9 Inhibition Studies  
Figure 4A presents typical change in the NMR signal for the MMP-9 cleavable peptide 
(TY-26) in the presence of MMP-9 enzyme over 20 h. It can be seen that the intact peptide 
signal (-117.5 ppm) gradually decreases and a degradation product signal (-117.2 ppm) 
appears. The degradation product signal becomes clearly visible after 20 h. The degradation 
rate constant for the MMP-9 cleavable peptide was 4.5×10-6s-1. On the other hand, the cleavage 
of TY-26 was completely blocked by the MMP-9 enzyme in the presence of MMP-9 inhibitor 
NPs (Figure 4B). In the duplicate run, it was found that the cleavage of TY-26 decreased to 
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1.9×10-6s-1 in the presence of MMP-9 enzyme and MMP-9 inhibitor NPs (Supplementary 
Figure S7). The variations in the cleavage of TY-26 could be due to the impurities in the NPs. 
The TY-26 did not degrade noticeably in the presence of the TNCB buffer (Figure S8). Also, 
MMP-9 non-responsive peptide (TY-27) did not degrade in the presence of MMP-9 (Figure 
S9). These control tests suggest inhibition of TY-26 degradation in the presence of MMP-9 
enzyme and MMP-9 inhibiting NPs. 
3.3.Non-Toxicity of MMP-9 Inhibiting Nanoparticles  
Figure 5 shows the outcomes of the experiment assessing the potential effects of the MMP-
9 inhibiting NPs on LDH release. An increase in LDH release indicates increased cell death. 
The NPs at the tested concentrations did not induce any LDH release that was significantly 
different to that of negative. The percentage LDH release for the negative control was 18.2 ± 
2.6%, while for the NPs at 0.06 mg/mL, 0.14 mg/mL and 0.25 mg/mL it was 19.3 ± 3.3%, 19.3 
± 4.7% and 17.1 ± 2.6%, respectively. One-way-ANOVA did not show a statistical difference 
between the control cells and treated cells (all concentrations) in percentage of LDH release 
(P=0.9).  
3.4.In Vitro Disintegration of MMP-9 Inhibiting Nanoparticles Using Dialysis 
The disintegration (release) studies were conducted to determine whether the MMP-9 
inhibiting NPs would dissemble upon dilution, for example after intravenous injection. Figure 
6 presents that fluorescence intensity increased slightly from 155.7 ± 28.7 a.u. to 235.2 ± 33.9 
a.u. in the release media after 6 h incubation of the NPs in 40 mL of distilled water. A typical 
fluorescence curve is presented in Figure S10. This indicates that MMP-9 inhibiting NPs would 
have critical micelle (aggregation) concentration much less than 37 mg/L. However, the 
fluorescence intensity increased significantly from 158.7 ± 30.8 a.u. to 445.1 ± 68.1 a.u. in the 
release media for the MMP-9 inhibiting NPs in 24 h, when these were incubated with FBS. 
However, the degradation appeared in a two-step process. It can be seen from Figure 6 that in 
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the step-one the fluorescence intensity increased only from 158.7 ± 30.8 a.u. to 218.9 ± 27.9 
a.u. in 5 h incubation in the presence of FBS. Then, the fluorescence intensity jumped to 445.1 
± 68.1 a.u. in 24 h incubation in the presence of FBS. This observation suggested the 
degradation of the NPs by the enzymes in the serum, and not disintegration of the NPs up on 
dilution. Furthermore, the MMP-9 inhibiting NPs would not degrade rapidly by the serum 
enzymes.  
3.5.The In Vitro BBB Transmigration of MMP-9 Inhibiting Nanoparticles  
The TEER values of BBB model reached 239 ± 28  cm2 after 48 h of incubation; and 
slightly increased to 250± 13  cm2 after the treatment of the cells with MMP-9 inhibiting 
NPs. Histamine treatment resulted in the reduction of TEER values from 200 cm2 to 62  
cm2. Whereas treatment with cimetidine helped the TJ to restore their integrity up to 145 cm2 
as shown in Figure 7. 
The MMP-9 inhibiting NPs showed an ability to cross the in vitro BBB (Figure 8). The 
percentage of NPs that crossed the BBB model reached 23 ± 5% after two hours of incubation 
and reached 28 ± 3% at 5 h. However, Figure 8 shows a decrease, although not significantly, 
in the number of NPs that transmigrated from the apical side of the BBB model to the 
basolateral side after 5 h and reduced to 22% ± 3% at 24 h. This trend was more pronounced 
when Papp was calculated (Figure 9). It can be seen from Figure 9 that Papp decreased after 2 
h post incubation, indicating that there was not net increase in the transmigration of NPs in the 
basolateral compartment. The negative values of Papp highlights net decrease in the total 
number of NPs in the basolateral compartment. This observation suggests return of some NPs 
from the basolateral side of the model to the apical side. After treatment of cell with the NPs, 
it was observed that only 0.5 ± 0.1% of FITC-dextran crossed the in vitro BBB model, 
indicating NPs did not compromise the BBB permeability.  
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4. Discussion  
This work demonstrated the preparation of hard-core peptide-based NPs containing brain 
targeting ligand, with MMP-9 inhibition properties. The NPs were shown to be non-toxic with 
an average diameter of 200 nm. The NPs were able to reduce the activity of the MMP-9 enzyme 
either completely or by half in a 19F NMR based assay. Importantly, the NPs maintained their 
integrity upon dilution, but could be hydrolysed gradually by the enzymes in the serum. 
Furthermore, the MMP-9 inhibiting NPs showed the ability to cross an in vitro BBB model. In 
this work, we did not investigate the ability of NPs without brain targeting ligands. This was 
based on observations made by other investigators that inclusion of brain targeting ligands 
improves significantly the ability of NPs to cross the BBB following intravenous 
administration.43-47  
In a previous study, magnetic NPs-bound TMP-1 had the size of 10 ± 3 nm,17 and similarly 
surface adsorbed siRNA on quantum dots (QD–siRNA nanoplexes) had a diameter of 15-20 
nm.16 These are much smaller than the MMP-9 inhibiting NPs we present in this work, 
however, our NPs exhibited an irregular shape compared to previous work.16,17 The PdIs were 
similar for the magnetic NPs,17 and MMP-9 inhibiting NPs of this work. In another study, the 
diameters of PLGA NPs encapsulating TMP-1 were between 80 nm and 430 nm (depending 
on TMP-1 loading);18 and the PLGA NPs had spherical shape. Furthermore, Cu@mSiO2-PEG 
NPs showed MMP-9 inhibiting properties in HeLa cells.48 These NPs also had an irregular 
shape, but with an average diameter of 179.7 nm.49 Therefore, the MMP-9 inhibiting NPs of 
our work had sizes within the range of previous works. Moreover, the relatively large size of 
these NPs would be expected to make them reside at the basal lamina of the BBB.50 This would 
be beneficial, as MMP-9 at the BBB increases the permeability of the BBB, which results in 
neuronal damage.51  
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Researchers have developed formulations to reduce the expression of MMP-9. For 
example, Cu@mSiO2-PEG NPs reduced the expression of MMP-9 in HeLa cells, 
48 and QD–
siRNA nanoplexes reduced the expression of MMP-9 in brain microvascular endothelial cells 
by 78%. In addition, solid lipid NPs-encapsulating MMP-9 downregulating shRNA-reduced 
the secretion of MMP-9 in human corneal epithelial cells by 30%.52 The ability of our NPs to 
inhibit MMP-9 was investigated through the use of a specially-designed and optimised 19F 
NMR based assay that measures the remaining 19F-labelled peptide upon treatment with MMP-
9 compared with control. MMP-9 inhibiting NPs of this study had concentration of 480 µM 
and they reduced the activity of MMP-9 completely or by half. The variation in the MMP-9 
inhibiting properties of the NPs could be due to the impurities in the NPs. Therefore, further 
experiments are required using purified conjugated peptides to verify this hypothesis. The 
CTTHWGFTLC peptide inhibited MMP-9 with an IC50 of about 500 µM.
31 Therefore, the 
MMP-9 inhibiting NPs containing CTTHWGFTLC peptide showed comparable inhibiting 
activity to the parent peptide alone in solution. In another study, gold NPs stabilised by 
polyvinylpyrrolidon (PVP) blocked completely MMP-9 activity at 400 µg/mL.53 The gold 
nanoparticle concentration was significantly lower than the MMP-9 inhibiting nanoparticle 
concentration (1.25 mg/mL) in our MMP-9 inhibiting study. Hence, the gold NPs are more 
efficient in inhibiting MMP-9 compared to peptide-based MMP-9 inhibiting NPs. However, it 
should be noted that gold NPs may activate microglia,54 while the MMP-9-inhibiting NPs can 
be digested by enzymes in the body.  
The MMP-9 inhibiting NPs in this work, up to 250 µg/mL, did not present significant 
toxicity towards HeLa cells, and other nanoparticle formulations also showed similar 
findings;17,52,53 while PVP-coated platinum NPs did show cell toxicity at 100 µg/mL 
concentration.53 Furthermore, magnetic NPs-bound TMP-1 NPs showed cell toxicity at 
concentrations above 10 µg/mL.17 These observations indicate that the MMP-9 inhibiting NPs 
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in our work, even at concentrations as high as (250 µg/mL), do not present any toxicity issues. 
Unlike certain previously reported formulations.17,53 In this work, we evaluated the toxicity of 
MMP-9 inhibiting NPs in HeLa cells (as divide and grow unusually fast), similar to a previous 
work.55 This was mainly due to the presence of serum in the culture media of hCMEC/D3, 
which potentially digest the MMP-9 inhibiting peptides, and mask the toxic effects of the NPs. 
However, the TEERs values of the BBB model did not decrease following treatment with the 
MMP-9 inhibiting NPs. This could also show nontoxic effects of the NPs towards hCMEC/D3 
cells, as it has been shown that cytotoxic materials decreases TEER values of in vitro BBB 
models.56 Perhaps, the toxicity studies may also be conducted in brain endothelial cells and 
neuronal cells.16,17  
Amongst the nanoparticle formulations discussed above, the PVP stabilised gold NPs,53 
CuS@mSiO2-PEG NPs,48 and MMP-9 inhibiting NPs of our work did not require loading of 
an active ingredient, such as TIMP-1.16-18,52 Therefore, the MMP-9 inhibiting NPs of our study 
would have fewer challenges in scale-up compared to the other approaches for the treatment of 
brain diseases, when undesired activity of MMP-9 increases in the brain. However, it should 
be noted that, we noticed a slow conjugation process for the cholesteryl chloroformate. Hence, 
further research will be required to optimise this process, or even to replace the cholesteryl 
motif with a more synthetically-tractable hydrophobic peptide sequences that will lead to the 
formation of NPs by self-assembly of these amphiphilic peptides in aqueous media;57-63 leading 
to improved scale-up. In this approach, it would be required to conduct studies using circular 
dichroism to determine the roles of peptide secondary structure in the formation of self-
assembled nanoparticles.64  
Here, we found that HAI peptide would conjugate more effectively to the MMP-inhibiting 
peptide (CTTHWGFTLC) compared to Mini-app3 (CKAPETALC). In a previous work 
polysorbate 80 was used to facilitate crossing the BBB by NPs.18 While in another work, a 0.08 
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T magnetic field was employed to allow the magnetic NPs to cross an in vitro model of the 
BBB.17 The use of brain targeting ligand makes no need to apply for a magnetic field. Also the 
use of polysorbate 80 may accumulate the NPs in the lungs.19 However, only 28% (at the most) 
of MMP-9 inhibiting NPs of our work crossed the in vitro BBB, whilst this amount can reach 
around 40% for magnetic NPs under the influence of a magnetic field. It should be noted that 
the in vitro BBB model using hCMEC/D3 may not represent the physiological BBB barrier. 
As it has been shown that the barrier could be impermeable to FITC-dextran (MW 70 kDa) but 
permeable to smaller molecular weight of FITC-dextran (MW 4 kDa).65 Furthermore, the BBB 
model used in our work lacked other components of the BBB such as astrocytes and pericytes, 
or being dynamic.66-68 However, a good correlation has been observed between the in vivo and 
in vitro data by using a static monolayer of brain endothelia cells (like our model).64,69 
Ultimately, in vivo studies would further indicate the ability of the MMP-9 inhibiting NPs 
crossing the BBB. As in vivo studies will take into account crossing the BBB, binding to plasma 
proteins, clearance by the reticuloendothelial system, and enzymatic cleavage in the serum.70 
The MMP-9 inhibiting NPs of our work showed crossing of the in vitro BBB model 2 h after 
incubation. This is in agreement with previously published work.17 It may be argued that during 
this period part of NPs might be cleared from the blood by the reticuloendothelial system. In 
vivo studies showed that significant brain uptake occured for exosome coated gold 
nanoparticles, when after 3 h only 10% of the exosomes crossed the in vitro BBB model.69 This 
is to indicate that when in vitro data shows low levels of NPs crossing the BBB, the in vivo 
data may show complete the opposite. 
Amphiphilic peptides containing cholesterol self-assembled to form nanoparticles and a 
critical micelle concentration (CMC) was measured.37 Based on this observation, we speculate 
that NPs of our study formed by self-assembly. However, the long-duration of sonication to 
form irregular shape nanoparticles created a doubt that whether the amphiphilic peptides could 
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be dispersed at the molecular level in an aqueous media for CMC measurements. Although this 
property created an advantage that the NPs did not disintegrate upon dilution. 
The availability of MMP-9 inhibiting NPs (like the ones in this study) can be useful for the 
treatment of ischemic stroke.71 In a previous work, polymeric NPs were prepared by the 
copolymer of poly(ethylene glycol)-b-poly(D,L-lactide), and loaded with curcumin. The NPs 
had size distribution of 147.8 ± 5.7 nm. The nanocarriers were NOT decorated with brain 
targeting ligand, and they were injected intravenously to mice with ischemia/reperfusion injury. 
The nanocarriers appeared in the regions with ischemia/reperfusion injury, and reduced the 
expression of the MMP-9 in the ischemic cortex, which helped reducing the infarct size and 
improving function recovery.72 The nanocarriers might have crossed the BBB through 
compromised tight junctions in the ischemic region.72 It should be noted that the BBB is rapidly 
disrupted and the disruption remains for days in acute ischemic stroke.73,74 The BBB 
permeability increased from 0.83 mL/100 g per minute to 1.15 mL/100 g per minute in the 
infarcted region of human brain.73 Therefore, the BBB permeability increases for about 38%. 
This is still a strong barrier to allow sufficient NPs to cross the BBB. Therefore, as shown 
previously, more NPs penetrated to the brain, when the surface of NPs was decorated with 
brain targeting ligand, which presented with significantly improved therapeutic outcome.75 
These observations indicate that the surface of NPs should be decorated with brain targeting 
ligand to achieve significant/desired clinical outcomes for the treatment of ischemic stroke. 
Furthermore, patients with hyperglycaemia tend to have increased serum MMP-9 levels, and 
this makes them prone to stroke, due to compromised BBB.76 Hence, a safe MMP-9 inhibiting 
NP formulation can be beneficial for these patients.  
A previous study administered about an intraperitoneal dose of 0.5 mg/kg (12.43 µg per 
mouse) of a triple-helical MMP-9 inhibiting peptide to experimental autoimmune 
encephalomyelitis (EAE) mice; and the clinical severity of EAE reduced from day 12 (post 
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EAE induction) afterwards.77 As these peptides did not contain brain-targeting ligand, but 
showed clinical efficacy, therefore it may be suggested that similar dose would be suitable for 
in vivo work. However, by considering that typically 1% of intravenously administered NP 
dose reaches the brain,75 and 35 µL as CSF volume of mouse, then the MMP-9 inhibiting NP 
concentration in the brain will be 3.5 mg/mL with the dose of 12.42 µg per mouse. As our in 
vitro data showed reducing MMP-9 activity at 1.25 mg/mL, then for in vivo studies, the dose 
of 0.5 mg/kg may be sufficient to inhibit MMP-9 in the mouse brain. These calculations are 
based on the assumption that MMP-9 inhibiting NPs would cross the BBB in vivo.  
There are limitations to this research. First, the MMP-9 inhibiting NPs should be tested in 
vivo where elevated MMP-9 levels in the brain cause neurodegeneration for example in EAE 
mice as reported previously.77,78 This also would help to test the effects of protein corona on 
the efficacy of the NPs on inhibiting MMP-9. Second, peptides with different MMP-9 
inhibitory activity should be included in the structure of NPs to test that whether MMP-9 
inhibitory activity is derived solely from the MMP-9 inhibiting peptide. Third, the blood 
compatibility of the MMP-9 inhibiting NPs should be tested such as complement activation, 
haemolysis and platelet aggregation. In this work, we did not investigate the potential inhibition 
of other enzymes in the brain such as MMP-2 by our MMP-9 inhibiting NPs.77 Therefore, this 
aspect should be taken into account, if exclusive inhibition of MMP-9 is needed. 
5. Conclusion  
Our work presents proof-of concept for the development of peptide based MMP-9 
inhibiting NPs, which were able to reduce the activity of MMP-9 considerably. The NPs 
included the brain targeting HAI peptide ligand, which helped to cross an in vitro model of the 
BBB. Importantly, the NPs did not show cell toxicity up to 250 µg/mL concentration. 
Moreover, as compared to previous reported nanoparticle based formulations for brain drug 
delivery, these provide the advantages of scalability and of not needing to load the active 
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ingredient. Furthermore, the NPs had average diameter of 202.8 ± 105.6 nm with PdI of 0.2, 
which make them suitable to remain in the basal lamina of the BBB, where the activity of 
MMP-9 released from the endothelial cells or macrophages would compromise the BBB 
permeability. We envisage that the in vitro proof of concept described herein can serve as a 
platform for new in vitro and in vivo studies into the development a new class of brain-targeting 
MMP-9 inhibitors for the treatment of progressive neurodegenerative diseases and brain 
injuries, when undesired activity of MMP-9 increases. 
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8. List of Figures and Tables 
Table 1: Peptide sequences that were synthesised and theoretical molecular mass, where C was 
TRT protected. 
Figure 1: A) Schematic diagram of the formation of self-assembled MMP-9 inhibiting NPs by 
amphiphilic peptides. B) Ball and stick presentation of the MMP-9 inhibiting amphiphilic 
compound: Cholesterol-CTTHWGFTLCHAIYPRH. Cholesterol is presented as yellow ball 
and sticks. 
Figure 2: Particle size distribution report of MMP-9 inhibiting nanoparticles obtained by the 
DLS method. This figure shows three different measurements. The average particle size and 
PdI are presented at the top of figure. 
Figure 3: TEM images of MMP-9 inhibiting NPs, presenting irregular shape of NPs. The scale 
bar is 500 nm. 
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Figure 4: 19F NMR data presenting the inhibition of MMP-9 by MMP-9 inhibiting NPs. A) 
Cleavage of a MMP-9 cleavable peptide (TY-26) by MMP-9 enzyme is represented by 
disappearing signal at -117.5 ppm and appearance of enzyme degradation product signal at -
117.2 ppm, B) The inhibition of TY-26 cleavage by MMP-9 inhibiting NPs in the presence of 
MMP-9 enzyme is shown by persistent signal at -117.6 ppm and no any other signals. 
Figure 5: Cell toxicity of MMP-9 inhibiting NPs towards HeLa cells measured by LDH 
release. Lack of toxicity of MMP-9 inhibiting NPs is indicated by LDH release comparable to 
control tests. LDH release is expressed as mean ± SD (n=3).  
Figure 6: Release of MMP-9 inhibiting NPs (MIB-NPs) from a dialysis bag with or without 
the presence of foetal bovine serum (FBS), presenting degradation of MIB-NPs by enzymes in 
the FBS and slight disintegrations of MIB-NPs upon dilution. Error bars present SD (n=3). 
Figure 7: TEER values for in vitro BBB prepared by hCMEC/D3 cells seeded at 90000/insert 
after 24 h, 36 h, post histamine and post cimetidine treatment, presenting formation of a 
biological barrier that can be compromised by pharmacological compounds (histamine) and 
restated by pharmacological agents (cimetidine). Error bar indicate SD (n=3). 
Figure 8: Transmigration study of MMP-9 inhibiting NPs using hCMEC/D3 in vitro BBB 
model, demonstrating ability of the NPs to cross the BBB after 2 h incubation at 37C. Also, 
the figure presents gradual drop in transmigrated NPs to the basolateral compartment after 5 h 
incubation. Error bars present SD (n=3). 
Figure 9: The relationship between in vitro brain permeability and time for MMP-9 inhibiting 
NPs using hCMEC/D3 cell line. It can be seen that Papp reduced considerably after 2 hr 
incubation and it was negative after 5 hr incubation. This observation suggests reverse of NPs 
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Figure 1: A) Schematic diagram of the formation of self-assembled MMP-9 inhibiting NPs by 







Figure 1: B) Ball and stick presentation of the MMP-9 inhibiting amphiphilic compound: 





Figure 2: Particle size distribution report of MMP-9 inhibiting nanoparticles obtained by the 
DLS method. This figure shows three different measurements. The average particle size and 





Figure 3: TEM images of MMP-9 inhibiting NPs, presenting irregular shape of NPs. The scale 





Figure 4: 19F NMR data presenting the inhibition of MMP-9 by MMP-9 inhibiting NPs. A) 
Cleavage of a MMP-9 cleavable peptide (TY-26) by MMP-9 enzyme is represented by 
disappearing signal at -117.5 ppm and appearance of enzyme degradation product signal at -
117.2 ppm, B) The inhibition of TY-26 cleavage by MMP-9 inhibiting NPs in the presence of 





Figure 5: Cell toxicity of MMP-9 inhibiting NPs towards HeLa cells measured by LDH 
release. Lack of toxicity of MMP-9 inhibiting NPs is indicated by LDH release comparable to 






Figure 6: Release of MMP-9 inhibiting NPs (MIB-NPs) from a dialysis bag with or without 
the presence of foetal bovine serum (FBS), presenting degradation of MIB-NPs by enzymes in 





Figure 7: TEER values for in vitro BBB prepared by hCMEC/D3 cells seeded at 90000/insert 
after 24 h, 36 h, post histamine and post cimetidine treatment, presenting formation of a 
biological barrier that can be compromised by pharmacological compounds (histamine) and 






Figure 8: Transmigration study of MMP-9 inhibiting NPs using hCMEC/D3 in vitro BBB 
model, demonstrating ability of the NPs to cross the BBB after 2 h incubation at 37C. Also, 
the figure presents gradual drop in transmigrated NPs to the basolateral compartment after 5 h 







Figure 9: The relationship between in vitro brain permeability and time for MMP-9 inhibiting 
NPs using hCMEC/D3 cell line. It can be seen that Papp reduced considerably after 2 hr 
incubation and it was negative after 5 hr incubation. This observation suggests reverse of NPs 
from the basolateral compartment to the apical compartment. Error bars present SD (n=3). 
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